We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




SuperNova Diagnostics Enters Agreement with KSB Diagnostics of China

By LabMedica International staff writers
Posted on 23 Mar 2011
SuperNova Diagnostics, Inc. More...
(Germantown, MD, USA; and London, United Kingdom), a privately-held global diagnostics company for human and nonhuman health applications, signed an agreement with Shenzhen Kang Sheng Bao Bio-Technology Co., Ltd. (KSB; Shenzhen, China), a biotechnology diagnostics company specializing in research, manufacture, and distribution of in vitro diagnostic kits and research reagents in China and affiliated markets. Financial terms of the agreement were not disclosed.

AmpCrystal, SuperNova Diagnostics' lead technology with multiple product formats, allows minimally trained individuals (advanced CLIA-waived) to test for a wide range of protein analytes. It can detect directly unamplified DNA in human, animal, or environmental samples. AmpCrystal is hyper-dense, energy-mediated nanocrystals that can be utilized in a wide variety of diagnostic applications and configurations. The technology platform lends itself to both forward-integration into new product formats as well as backward compatible into existing open and closed diagnostic systems.

With three integrated capabilities (sample collector/processor, analytical disposable, and the readout device), AmpCrystal technology is simpler, more robust, faster, and significantly less expensive than existing POC systems.

A powerful nanochemistry, AmpCrystal, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without polymerase chain reaction (PCR) with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtiter, microarrays, closed systems, research products, and OEM).

"We are delighted to announce this agreement with KSB Diagnostics, a leader in China and Asia for diagnostics," said Neil Campbell, president & CEO of SuperNova Diagnostics. "This collaborative relationship allows SuperNova and KSB to expand R&D, manufacturing, and commercialization into one of the world's largest markets."

Through cooperation with its worldwide partners and introduction of advanced technology in the world, Shenzhen Kang Sheng Bao Bio-Technology Co. Ltd. provides the innovating diagnostic kits. Its goals are to make great efforts to serve the rapidly developing market in China and become one of the well-known corporations in the field of in vitro diagnostic reagents.

Related Links:
SuperNova Diagnostics, Inc.
Kang Sheng Bao Bio-Technology Co., Ltd.


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.